Oxis Turbohaler (Formoterol Fumarate Dihydrate)

Formoterol fumarate dihydrate is a bronchodilator that acts on the airway smooth‑muscle pathway to improve airflow in obstructive lung disease.

• Asthma: improves symptom control and reduces the need for rescue inhaler use.
• Chronic obstructive pulmonary disease (COPD): provides sustained bronchodilation and helps decrease exacerbation frequency.
• Exercise‑induced bronchoconstriction: maintains airway patency during physical activity.

• Formoterol binds selectively to β2‑adrenergic receptors on airway smooth‑muscle cells, activating adenylate cyclase and increasing cyclic AMP levels. The rise in cAMP leads to relaxation of smooth‑muscle fibers, producing a rapid and prolonged bronchodilatory effect that improves airflow in the bronchi and bronchioles.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects

• Tremor: mild, transient shaking of the hands.
• Headache: dull or pressure‑type headache.
• Throat irritation: mild discomfort or dryness in the throat.
• Cough: occasional dry cough after inhalation.
• Palpitations: sensation of rapid or irregular heartbeat.
• Nasal congestion: mild blockage of the nasal passages.

Serious or Rare Side Effects

• Paradoxical bronchospasm: sudden worsening of breathing difficulty.
• Cardiovascular events: arrhythmia, angina, or hypertension.
• Hypokalemia: low blood potassium levels.
• Severe allergic reaction: rash, itching, swelling, or anaphylaxis.
• Hyperglycaemia: elevated blood glucose in susceptible individuals.
• Pulmonary oedema: fluid accumulation in the lungs.

When using Oxis Turbohaler, consider the following safety measures:

• Assess respiratory status: confirm diagnosis and severity before initiating therapy.
• Review cardiac history: patients with arrhythmias or coronary disease need careful monitoring.
• Monitor potassium levels: especially in patients on diuretics or with renal impairment.
• Avoid abrupt discontinuation: sudden cessation may worsen bronchospasm.
• Educate on inhaler technique: ensure correct use to maximise drug delivery.
• Store at ambient temperature: keep below 25°C, protect from moisture and direct sunlight.

Formoterol may interact with several drug classes; clinicians should evaluate potential risks.

Major Interactions (Avoid)

• Non‑selective β‑blockers: may diminish bronchodilator effect and precipitate bronchospasm.
• Monoamine oxidase inhibitors (MAOIs): can increase risk of cardiovascular side effects.

Moderate Interactions (Monitor Closely)

• Diuretics: may exacerbate hypokalemia.
• Theophylline: additive stimulant effect on the heart.
• Anticholinergic bronchodilators: may increase risk of tachycardia.
• Corticosteroids: combined use may enhance systemic exposure.
• Antidepressants (SSRIs): potential for mild QT‑interval changes.